This concept was validated in clinical trials using CD25 monoclonal antibodies in conjunction with tumor antigen peptide vaccines, in which patients were administered a single dose of CD25 monoclonal antibody one week prior to vaccine treatment (135). This evidence concerns the gene IL2RA and neoplasm.